Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nitric Oxide is starting to be used.

<< Previous

Bullboard Posts

Next >>

Comment by losingmyshirton Sep 10, 2020 9:31am

123 Views

Post# 31532343

RE:RE:Nitric Oxide is starting to be used.

Mateo,

INHALED NITROUS OXIDE. Yes we know it works.
We are not dealing with INHALED..

Nowhere, anywhere is there information about R107 which is injectable. and there is no news on R107 because there is little to no interest in this method.
Are you confused or what?

<< Previous

Bullboard Posts

Next >>

New CEO leads Sonoro Energy's vision to expand in MENA